Comprehensive medication guide to Foundayo including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$25/month copay with commercial insurance and the Foundayo Savings Card (expires 12/31/2026); ~$50/month for eligible Medicare Part D enrollees expected starting July 1, 2026. Prior authorization required by most plans.
Estimated Cash Pricing
$149/month for the 0.8 mg starter dose, $199/month for 2.5 mg, and $299/month for maintenance doses (5.5 mg–17.2 mg) through LillyDirect self-pay. No generic available.
Medfinder Findability Score
45/100
Summarize with AI
On this page
Foundayo (orforglipron) is an oral prescription medication approved by the FDA on April 1, 2026 for chronic weight management in adults. Made by Eli Lilly, it is the first small-molecule, non-peptide GLP-1 receptor agonist approved for weight loss — and the only GLP-1 pill that can be taken at any time of day without food or water restrictions.
Foundayo belongs to the same class of medications as Ozempic, Wegovy, and Zepbound, but its unique small-molecule structure allows it to be swallowed as a daily pill rather than injected weekly. It works by activating GLP-1 receptors in the brain and digestive system, reducing appetite, promoting fullness, and slowing gastric emptying.
In Phase 3 clinical trials (ATTAIN-1), patients on the highest dose lost an average of 27.3 pounds (12.4% of body weight) over 72 weeks, compared to 2.2 pounds with placebo. Foundayo is approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Foundayo (orforglipron) works by binding to and activating glucagon-like peptide-1 (GLP-1) receptors in the brain and digestive tract. GLP-1 is a natural hormone released after eating that signals fullness and regulates appetite. By continuously activating these receptors, Foundayo creates a sustained satiety signal that reduces hunger throughout the day.
Unlike peptide-based GLP-1 drugs (semaglutide, liraglutide) that require injection, orforglipron is a small-molecule drug — a compact, chemically synthesized compound that survives digestion and absorbs reliably through the gut. This molecular structure is why Foundayo can be taken as a pill with no food or water restrictions. Most GLP-1 peptides are destroyed by digestive enzymes before reaching the bloodstream.
The three key effects of Foundayo's GLP-1 receptor activation are: (1) appetite suppression through brain receptor signaling; (2) delayed gastric emptying, keeping food in the stomach longer so patients feel fuller after smaller meals; and (3) modest blood sugar regulation by stimulating insulin release in response to meals and reducing glucagon. Together, these effects naturally reduce caloric intake and produce gradual, sustained weight loss.
0.8 mg — tablet
Starting dose; take once daily at any time
2.5 mg — tablet
Increase to this dose after ≥30 days at 0.8 mg
5.5 mg — tablet
Increase to this dose after ≥30 days at 2.5 mg
9 mg — tablet
Increase to this dose after ≥30 days at 5.5 mg
14.5 mg — tablet
Increase to this dose after ≥30 days at 9 mg
17.2 mg — tablet
Maximum dose; increase after ≥30 days at 14.5 mg
Foundayo is newly FDA-approved (April 1, 2026) and patients are experiencing uneven pharmacy availability as a result. This is a launch-ramp distribution issue rather than a formal FDA-designated shortage — the drug exists and is being manufactured, but not all pharmacies have stocked it yet. Its findability score reflects this launch-period access challenge.
The most reliable current sources are LillyDirect (shipping since April 6, 2026) and Amazon Pharmacy. Retail pharmacy availability is improving but remains inconsistent across locations in mid-2026. Availability is expected to normalize significantly in the second half of 2026 as Medicare coverage begins (July 2026) and insurance formularies solidify.
If you're having trouble finding Foundayo at your local pharmacy, medfinder calls pharmacies near you to find which ones have it in stock. You provide your medication, dose, and ZIP code — medfinder does the calling and texts you the results.
Foundayo is not a controlled substance (no DEA schedule), so any licensed healthcare provider with prescribing authority can write a Foundayo prescription without special registration. There are no prescribing restrictions or special certification requirements.
Providers who commonly prescribe Foundayo include:
Foundayo is particularly well-suited to telehealth prescribing since no injection training is required. Multiple platforms (Walgreens Health, Ro, Klinic, Hims & Hers) began offering Foundayo prescriptions on the day of FDA approval. Telehealth consultations are often available within 24–48 hours and are a convenient option for patients who don't yet have an established obesity medicine or PCP relationship.
No. Foundayo (orforglipron) is not a controlled substance and has no DEA schedule. It does not have addiction, dependence, or abuse potential. Any licensed healthcare provider — including primary care physicians, nurse practitioners, physician assistants, and telehealth providers — can prescribe Foundayo without any special DEA registration or controlled substance prescribing authority.
Because Foundayo is not controlled, prescriptions can be written by providers across all specialties, called into pharmacies electronically or by phone without special procedures, and refilled without the restrictions that apply to Schedule II–V controlled substances. There are no quantity limits or prescription monitoring program (PMP) reporting requirements related to controlled substance status.
The most common side effects reported in ≥5% of patients in the ATTAIN clinical trials include:
Serious side effects (stop medication and seek care):
Know what you need? Skip the search.
Wegovy (semaglutide)
Weekly injectable GLP-1; ~15% average weight loss at 72 weeks; also available as a strict-protocol oral pill. More widely stocked than Foundayo in mid-2026.
Zepbound (tirzepatide)
Weekly injectable GLP-1/GIP dual agonist by Eli Lilly; ~20–21% average weight loss; higher efficacy than Foundayo but requires injection. $299/month self-pay through LillyDirect.
Ozempic (semaglutide)
Weekly injectable GLP-1; FDA-approved for type 2 diabetes with significant weight loss benefit. Often prescribed off-label for obesity. May have better insurance coverage for patients with T2D.
Rybelsus (oral semaglutide)
Oral semaglutide tablet approved for type 2 diabetes; requires strict empty-stomach administration unlike Foundayo. Sometimes used off-label for weight loss.
Prefer Foundayo? We can find it.
Ritonavir (strong CYP3A4 inhibitor + OATP1B inhibitor)
majorSignificantly increases orforglipron blood levels. Avoid or cap Foundayo at 9 mg/day maximum.
Carbamazepine (strong CYP3A4 inducer)
majorSignificantly reduces orforglipron blood levels, reducing effectiveness. Avoid concomitant use.
Rifampin (strong CYP3A4 inducer)
majorSignificantly reduces orforglipron levels. Avoid concomitant use.
Other GLP-1 receptor agonists (Ozempic, Wegovy, Zepbound, etc.)
majorNever combine with another GLP-1 agonist — dramatically increases serious GI adverse reaction risk.
Simvastatin
moderateFoundayo significantly increases simvastatin acid levels, raising myopathy risk. Limit simvastatin to 20 mg/day. Switch to rosuvastatin or atorvastatin if higher statin doses needed.
Oral contraceptive pills
moderateGastric emptying delay may reduce absorption and effectiveness. Use backup contraception for 30 days after starting and after each dose increase.
Clarithromycin
moderateStrong CYP3A4 inhibitor; may increase Foundayo levels.
Cyclosporine
moderateCYP3A4 inhibitor; may increase Foundayo levels.
Insulin / sulfonylureas
moderateIncreased hypoglycemia risk when combined with Foundayo. Monitor blood glucose closely.
Foundayo (orforglipron) represents a genuine advancement in obesity pharmacotherapy — the first oral GLP-1 medication free of food and water restrictions, making treatment more accessible for the millions of patients who prefer a pill over a weekly injection. Its FDA approval in April 2026 under a historic 50-day review timeline reflects the urgency and priority placed on obesity treatment options.
Average weight loss of ~11–12% in clinical trials is meaningful, though modest compared to injectable GLP-1/GIP dual agonists. The lower average weight loss is offset by the dramatically simpler administration, lower self-pay cost ($149–$299/month vs $1,000+ for injectables), and the convenience that may improve long-term adherence. Foundayo is not right for everyone, but for patients who want an oral option, it fills an important gap.
The main near-term challenge is pharmacy availability, which is improving throughout 2026. If you've been prescribed Foundayo and are having trouble filling it, medfinder calls pharmacies near you to find which ones have your specific dose in stock — saving you hours of calling around yourself.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini